A Multi-Center, Open Label, Phase II Trial to Assess the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)

A Multi-Center, Open Label, Phase II Trial to Assess the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)

Trial Category:
Melanoma
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Southeast Nebraska Cancer Center, Lincoln, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members